María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
November 2019 Bonus ASH Annual Meeting Preview Edition (Volume 5, Issue 14)
This issue offers an inside look at this year’s annual meeting, advice for giving effective presentations, and more.
FDA Issues Guidelines for Regulating Health Artificial Intelligence
The FDA provided new guidance on the regulation of mobile health software and clinical decision support (CDS) tools that use artificial intelligence (AI). The...
Coagulation Conundrums: Managing Hemostatic and Thrombotic Complications in Young Women
In a case-based discussion as part of this year’s Education Program, Andra James, MD, MPH, and Margaret Ragni, MD, MPH, will answer challenging questions...
Democrats and Republicans Unveil Competing Drug Pricing Bills
Lowering drug costs is a major bipartisan voter issue, but tensions between parties have been escalating as Democrats introduced a bill that would allow...
FDA Approves Daratumumab-Based Quadruplet Regimen for Transplant-Eligible Myeloma
The U.S. Food and Drug Administration (FDA) approved the quadruplet regimen consisting of daratumumab, bortezomib, thalidomide, and dexamethasone to treat adult patients with newly...
Current Issue
November 2019 Bonus ASH Annual Meeting Preview Edition (Volume 5, Issue...
This issue offers an inside look at this year’s annual meeting, advice for giving effective presentations, and more.
